Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen’s Lumakras Succeeds In Confirmatory Lung Cancer Trial

Detailed Results To Be Presented Later

Executive Summary

Amgen said its KRAS G12C inhibitor Lumakras (sotorasib) bested docetaxel in a Phase III clinical trial on the primary endpoint of progression-free survival in second-line-plus non-small cell lung cancer.

You may also be interested in...



Expectations Of Lumakras ESMO Late-Breaker Build As Roche Plays KRAS Catch-Up

Amgen secured a last-minute slot as a late-breaker study with Lumakras, appearing to give it the upper hand on rival Mirati once again.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene’s confidence in IO/IO combinations.

Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?

Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146974

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel